205 related articles for article (PubMed ID: 27525431)
1. Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas.
Schwetz V; Librizzi R; Trummer C; Theiler G; Stiegler C; Pieber TR; Obermayer-Pietsch B; Pilz S
Metab Brain Dis; 2017 Feb; 32(1):155-161. PubMed ID: 27525431
[TBL] [Abstract][Full Text] [Related]
2. Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study.
Posawetz AS; Trummer C; Pandis M; Aberer F; Pieber TR; Obermayer-Pietsch B; Pilz S; Theiler-Schwetz V
BMC Endocr Disord; 2021 Apr; 21(1):81. PubMed ID: 33902531
[TBL] [Abstract][Full Text] [Related]
3. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
[TBL] [Abstract][Full Text] [Related]
4. Unusual late development of dopamine agonist resistance in two women with hyperprolactinaemia associated with transition from micro to macroadenoma.
McCall D; Hunter SJ; Cooke RS; Herron B; Sheridan B; Atkinson AB
Clin Endocrinol (Oxf); 2007 Jan; 66(1):149-50. PubMed ID: 17201816
[No Abstract] [Full Text] [Related]
5. Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
Vroonen L; Lancellotti P; Garcia MT; Dulgheru R; Rubio-Almanza M; Maiga I; Magne J; Petrossians P; Auriemma R; Daly AF; Beckers A
Endocrine; 2017 Jan; 55(1):239-245. PubMed ID: 27709470
[TBL] [Abstract][Full Text] [Related]
6. Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas.
Auriemma RS; Galdiero M; Vitale P; Granieri L; Lo Calzo F; Salzano C; Ferreri L; Pivonello C; Cariati F; Coppola G; de Angelis C; Colao A; Pivonello R
Neuroendocrinology; 2015; 101(1):66-81. PubMed ID: 25592453
[TBL] [Abstract][Full Text] [Related]
7. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
[TBL] [Abstract][Full Text] [Related]
8. [Current diagnosis and treatment of hyperprolactinemia].
Melgar V; Espinosa E; Sosa E; Rangel MJ; Cuenca D; Ramírez C; Mercado M
Rev Med Inst Mex Seguro Soc; 2016; 54(1):111-21. PubMed ID: 26820213
[TBL] [Abstract][Full Text] [Related]
9. Hyperprolactinemia in children and adolescents and longterm follow-up results of prolactinoma cases: a single-centre experience.
Kontbay T; Şıklar Z; Özsu E; Uyanık R; Bilici E; Ceran A; Berberoğlu M
Turk J Pediatr; 2022; 64(5):892-899. PubMed ID: 36305439
[TBL] [Abstract][Full Text] [Related]
10. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels.
Krysiak R; Okopien B
Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):251-6. PubMed ID: 25123447
[TBL] [Abstract][Full Text] [Related]
11. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
[TBL] [Abstract][Full Text] [Related]
12. Hyperprolactinaemia.
Prabhakar VK; Davis JR
Best Pract Res Clin Obstet Gynaecol; 2008 Apr; 22(2):341-53. PubMed ID: 17889620
[TBL] [Abstract][Full Text] [Related]
13. Nephrotic-range proteinuria in a patient with a giant prolactinoma.
Heras M; Iglesias P; Fernández-Reyes MJ; Sánchez R; Jiménez MJ; Muñoz H; Tajada P; Duarte J
Am J Kidney Dis; 2008 Jun; 51(6):1025-8. PubMed ID: 18455849
[TBL] [Abstract][Full Text] [Related]
14. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas.
Sala E; Bellaviti Buttoni P; Malchiodi E; Verrua E; Carosi G; Profka E; Rodari G; Filopanti M; Ferrante E; Spada A; Mantovani G
J Endocrinol Invest; 2016 Dec; 39(12):1377-1382. PubMed ID: 27245604
[TBL] [Abstract][Full Text] [Related]
15. Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study.
Nachtigall LB; Valassi E; Lo J; McCarty D; Passeri J; Biller BM; Miller KK; Utz A; Grinspoon S; Lawson EA; Klibanski A
Clin Endocrinol (Oxf); 2010 Jan; 72(1):53-8. PubMed ID: 19508591
[TBL] [Abstract][Full Text] [Related]
16. Massive reduction of tumour load and normalisation of hyperprolactinaemia after high dose cabergoline in metastasised prolactinoma causing thoracic syringomyelia.
van Uum SH; van Alfen N; Wesseling P; van Lindert E; Pieters GF; Nooijen P; Hermus AR
J Neurol Neurosurg Psychiatry; 2004 Oct; 75(10):1489-91. PubMed ID: 15377706
[TBL] [Abstract][Full Text] [Related]
17. Cabergoline, a hopeful medicine for prolactinomas and non-tumoral hyperprolactinemia.
Miki N
Intern Med; 2001 Sep; 40(9):845-6. PubMed ID: 11579939
[No Abstract] [Full Text] [Related]
18. Speed of response to dopaminergic agents in prolactinomas.
Hage C; Salvatori R
Endocrine; 2022 Mar; 75(3):883-888. PubMed ID: 34846682
[TBL] [Abstract][Full Text] [Related]
19. Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment.
Pirchio R; Auriemma RS; Solari D; Arnesi M; Pivonello C; Negri M; de Angelis C; Cavallo LM; Cappabianca P; Colao A; Pivonello R
Front Endocrinol (Lausanne); 2021; 12():769744. PubMed ID: 34917030
[TBL] [Abstract][Full Text] [Related]
20. Major depressive disorder induced by prolactinoma--a case report.
Liao WT; Bai YM
Gen Hosp Psychiatry; 2014; 36(1):125.e1-2. PubMed ID: 24182617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
